10 December, 2021 by The TZ Newswire Staff Comments Off on GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium
GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium
MELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium.
10 December, 2021 by The TZ Newswire Staff Comments Off on TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 63rd American Society of Hematology (ASH) Annual Meeting
NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today recapped the schedule of data presentations at the upcoming 63rd American Society of Hematology (ASH) annual meeting and exposition, to be held December 11 – 14, 2021, virtually and also live at the Georgia World Congress Center in Atlanta, Georgia.
10 December, 2021 by The TZ Newswire Staff Comments Off on Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal
Technical Paper on AnPac Bio Novel CDA Cancer Detection Technology Published by Peer-Reviewed International Medical Journal
PHILADELPHIA, Dec. 10, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd.
10 December, 2021 by The TZ Newswire Staff Comments Off on BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on December 6, 2021, the compensation committee of BridgeBio’s board of directors granted nine new employees restricted stock units for an aggregate of 12,073 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).
10 December, 2021 by The TZ Newswire Staff Comments Off on Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND
Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on ALS/MND
Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to Fast Disease Progression Phenotype at Baseline Majority of Initial Patients Enrolled in COURAGE-ALS Show Intended Middle to Fast Disease Progression Phenotype at Baseline
10 December, 2021 by The TZ Newswire Staff Comments Off on Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference
Avicanna to Participate in the Lytham Partners Winter 2021 Investor Conference
TORONTO, Dec. 10, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announced today it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the company will be participating in a webcasted Fireside Chat discussing its vision for 2022 and conducting 1×1 virtual investor meetings.
10 December, 2021 by The TZ Newswire Staff Comments Off on Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
Relay Therapeutics Announces Preclinical Data that Support Clinical Development of RLY-2608 as Both a Single Agent and in Combination
RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer models RLY-2608 combines with standard of care therapies to drive regressions in ER+/HER2- breast cancer models